Browse the Tables and Figures - SEER Cancer Statistics Review (CSR) 1975-2014

The navigation below allows you to jump to any table or figure within the SEER Cancer Statistics Review.

First select the CSR Section, then a Table/Figure from that section.
Use the Submit button to view the table or figure. You will have options to download a printer-friendly version (PDF) or the data table (CSV) as well.

To learn more about the Cancer Statistics Review and the statistics presented in this report, refer to the About the CSR(PDF, 524KB) and Technical Notes(PDF, 752KB) pages.

Section:

Table/Figure:

Download and Print: Download Printer-friendly PDF Download data

Table 1.23

U.S. Complete Prevalence Counts, Invasive Cancers Only, January 1, 2014^a
By Age at Prevalence

WARNING: The Prevalence Estimates presented on this page utilize a different tumor selection criteria from previous CSR releases and are NOT directly comparable to estimates from previous CSR releases.
Please see the Prevalence Comparison Chapter of this CSR for more information.

Site	Sex	Age at Prevalence
All Sites	Males	6,872,623	18,786	43,295	91,310	166,204	350,387	937,944	1,835,673	3,429,024
Females	7,866,096	17,222	37,437	93,801	242,346	639,430	1,424,917	1,995,951	3,414,992
Oral Cavity & Pharynx	Males	230,233	45	454	1,771	3,759	13,831	51,146	76,136	83,090
Females	116,669	107	542	1,594	4,163	8,877	21,084	30,278	50,024
Esophagus	Males	35,460	0	0	29	181	1,003	5,067	12,194	16,986
Females	10,087	0	0	0	44	190	1,441	2,846	5,566
Stomach	Males	55,180	0	11	168	589	2,749	8,310	14,682	28,670
Females	40,584	0	44	210	842	2,454	5,947	9,160	21,926
Colon & Rectum	Males	653,863	22	146	1,263	6,349	26,922	91,558	156,306	371,297
Females	663,384	0	261	1,482	6,650	24,542	80,676	130,589	419,183
Liver & Intrahepatic Bile Duct	Males	46,895	611	536	603	632	1,608	11,275	19,864	11,766
Females	19,876	418	591	486	471	1,059	3,816	6,321	6,715
Pancreas	Males	31,986	23	35	117	493	1,812	5,719	9,976	13,812
Females	32,682	0	23	347	628	1,721	5,972	8,601	15,389
Larynx	Males	80,249	0	0	80	285	1,810	10,178	23,304	44,592
Females	19,665	0	0	17	142	859	3,485	5,914	9,247
Lung & Bronchus	Males	234,540	34	98	470	1,266	5,330	26,088	64,649	136,605
Females	292,688	56	92	401	1,684	6,863	35,794	75,197	172,603
Melanoma of the Skin	Males	585,672	67	706	4,931	18,016	45,764	104,327	160,068	251,795
Females	583,679	107	813	10,439	36,175	74,208	129,434	142,681	189,821
Breast	Males	18,835	0	0	11	76	672	2,123	5,001	10,951
Females	3,327,552	11	47	3,031	38,197	215,565	597,561	910,098	1,563,042
Cervix	Females	256,078	0	81	2,075	14,495	40,908	60,284	61,931	76,305
Corpus & Uterus, NOS	Females	710,228	11	35	727	6,574	27,036	100,667	205,938	369,240
Ovary^d	Females	222,060	81	1,038	3,954	7,233	18,751	46,165	61,136	83,701
Prostate	Males	3,085,209	45	47	79	338	17,434	240,617	859,940	1,966,708
Urinary Bladder	Males	521,201	68	117	524	2,521	9,466	44,105	118,578	345,823
Females	175,239	79	34	246	972	3,819	14,892	36,157	119,040
Kidney & Renal Pelvis	Males	292,058	1,399	2,329	3,006	5,751	20,940	52,404	82,949	123,279
Females	191,167	1,616	2,455	3,238	5,310	13,603	33,033	47,535	84,377
Hodgkin Lymphoma	Males	105,489	209	2,301	9,666	16,550	23,334	24,766	18,035	10,629
Females	98,576	45	2,147	9,466	16,634	22,567	23,051	14,306	10,361
Non-Hodgkin Lymphoma	Males	350,647	831	4,019	8,336	14,494	30,378	61,177	88,332	143,081
Females	311,349	547	1,536	4,919	9,944	21,497	48,615	75,964	148,327
Myeloma	Males	65,283	0	18	87	605	3,537	10,446	19,742	30,849
Females	53,256	0	0	69	480	2,374	8,379	15,856	26,099
Leukemia	Males	219,989	6,599	13,513	14,405	12,981	16,403	29,092	46,712	80,285
Females	167,739	5,984	10,654	12,441	11,619	12,517	20,169	30,950	63,404
Acute Lymphocytic Leukemia	Males	44,485	5,568	11,217	11,145	7,420	5,011	2,295	1,096	732
Females	37,352	5,088	9,067	8,947	6,522	3,972	1,798	1,285	672

Site

Sex

Age at Prevalence

All Ages^c

Ages
0-9

Ages
10-19

Ages
20-29

Ages
30-39

Ages
40-49

Ages
50-59

Ages
60-69

Ages
70+

All Sites

Males

6,872,623

18,786

43,295

91,310

166,204

350,387

937,944

1,835,673

3,429,024

Females

7,866,096

17,222

37,437

93,801

242,346

639,430

1,424,917

1,995,951

3,414,992

Oral Cavity & Pharynx

Males

230,233

454

1,771

3,759

13,831

51,146

76,136

83,090

Females

116,669

107

542

1,594

4,163

8,877

21,084

30,278

50,024

Esophagus

Males

35,460

181

1,003

5,067

12,194

16,986

Females

10,087

190

1,441

2,846

5,566

Stomach

Males

55,180

168

589

2,749

8,310

14,682

28,670

Females

40,584

210

842

2,454

5,947

9,160

21,926

Colon & Rectum

Males

653,863

146

1,263

6,349

26,922

91,558

156,306

371,297

Females

663,384

261

1,482

6,650

24,542

80,676

130,589

419,183

Liver & Intrahepatic Bile Duct

Males

46,895

611

536

603

632

1,608

11,275

19,864

11,766

Females

19,876

418

591

486

471

1,059

3,816

6,321

6,715

Pancreas

Males

31,986

117

493

1,812

5,719

9,976

13,812

Females

32,682

347

628

1,721

5,972

8,601

15,389

Larynx

Males

80,249

285

1,810

10,178

23,304

44,592

Females

19,665

142

859

3,485

5,914

9,247

Lung & Bronchus

Males

234,540

470

1,266

5,330

26,088

64,649

136,605

Females

292,688

401

1,684

6,863

35,794

75,197

172,603

Melanoma of the Skin

Males

585,672

706

4,931

18,016

45,764

104,327

160,068

251,795

Females

583,679

107

813

10,439

36,175

74,208

129,434

142,681

189,821

Breast

Males

18,835

672

2,123

5,001

10,951

Females

3,327,552

3,031

38,197

215,565

597,561

910,098

1,563,042

Cervix

Females

256,078

2,075

14,495

40,908

60,284

61,931

76,305

Corpus & Uterus, NOS

Females

710,228

727

6,574

27,036

100,667

205,938

369,240

Ovary^d

Females

222,060

1,038

3,954

7,233

18,751

46,165

61,136

83,701

Prostate

Males

3,085,209

338

17,434

240,617

859,940

1,966,708

Urinary Bladder

Males

521,201

117

524

2,521

9,466

44,105

118,578

345,823

Females

175,239

246

972

3,819

14,892

36,157

119,040

Kidney & Renal Pelvis

Males

292,058

1,399

2,329

3,006

5,751

20,940

52,404

82,949

123,279

Females

191,167

1,616

2,455

3,238

5,310

13,603

33,033

47,535

84,377

Hodgkin Lymphoma

Males

105,489

209

2,301

9,666

16,550

23,334

24,766

18,035

10,629

Females

98,576

2,147

9,466

16,634

22,567

23,051

14,306

10,361

Non-Hodgkin Lymphoma

Males

350,647

831

4,019

8,336

14,494

30,378

61,177

88,332

143,081

Females

311,349

547

1,536

4,919

9,944

21,497

48,615

75,964

148,327

Myeloma

Males

65,283

605

3,537

10,446

19,742

30,849

Females

53,256

480

2,374

8,379

15,856

26,099

Leukemia

Males

219,989

6,599

13,513

14,405

12,981

16,403

29,092

46,712

80,285

Females

167,739

5,984

10,654

12,441

11,619

12,517

20,169

30,950

63,404

Acute Lymphocytic Leukemia

Males

44,485

5,568

11,217

11,145

7,420

5,011

2,295

1,096

732

Females

37,352

5,088

9,067

8,947

6,522

3,972

1,798

1,285

672

Footnotes:

^a U.S. 2014 cancer prevalence counts are based on 2014 cancer prevalence proportions from the SEER 9 registries (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta) and 1/1/2014 U.S. population estimates based on the average of 2013 and 2014 population estimates from the U.S. Bureau of the Census. Prevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 39 years (1975-2013).

^b Cases diagnosed more than 39 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000).

^c Due to rounding, the sum of the age specific estimates may not equal the all ages estimate.

Browse the SEER Cancer Statistics Review (CSR) 1975-2014

Table 1.23

U.S. Complete Prevalence Counts, Invasive Cancers Only, January 1, 2014a By Age at Prevalence

WARNING: The Prevalence Estimates presented on this page utilize a different tumor selection criteria from previous CSR releases and are NOT directly comparable to estimates from previous CSR releases. Please see the Prevalence Comparison Chapter of this CSR for more information.

Footnotes:

U.S. Complete Prevalence Counts, Invasive Cancers Only, January 1, 2014^a
By Age at Prevalence

WARNING: The Prevalence Estimates presented on this page utilize a different tumor selection criteria from previous CSR releases and are NOT directly comparable to estimates from previous CSR releases.
Please see the Prevalence Comparison Chapter of this CSR for more information.